NCT05270460Phase 2Completed

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

Study sponsor: Processa Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-09-29Actual
Enrollment · participants25Actual
Source updated2026-10-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate Description: Change from baseline in gastric emptying rate was determined by the AUC by Gastric Emptying Breath Test (GEBT) at Day 28 after administration of PCS12852 or placebo. Time frame: ~28 days Measure: Change in Gastric Emptying Rate From Baseline Using t50 Metric for Gastric Emptying Rate Description: Time for 50% gastric emptying (t50) metric assessed by the GEBT Time frame: ~28 days Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28 Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28. After: Measure: Change in Gastric Emptying Rate From Baseline as Determined by the Area Under the Curve (AUC) of the Gastric Emptying Rate Description: Change from baseline in gastric emptying rate was determined by the AUC by Gastric Emptying Breath Test (GEBT) at Day 28 after administration of PCS12852 or placebo. Time frame: ~28 days Measure: Change in Gastric Emptying Rate From Baseline Description: Time for 50% gastric emptying (t50) metric assessed by the GEBT Time frame: ~28 days Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 1 Measure: Concentrations of PCS12852 in Plasma - AUC0-last Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28 Measure: Concentrations of PCS12852 in Plasma - Cmax Description: PK parameters were estimated from concentration-time data using noncompartmental methods, as data permitted. Time frame: Day 28.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview